Naslov
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Autori
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith II, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse & Arlene Chan

Izvornik
Breast cancer research (1465-5411) 21 (2019), 1; 39-39

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
neratinib, breast cancer, PIK3CA alteration, predictive biomarker

Sažetak
Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We assessed the prognostic and predictive significance of PIK3CA alterations in patients in ExteNET. Methods Participants were women aged ≥ 18 years (≥ 20 years in Japan) with stage 1–3c (modified to stage 2–3c in February 2010) operable breast cancer, who had completed (neo)adjuvant chemotherapy plus trastuzumab ≤ 2 years before randomization, with no evidence of disease recurrence or metastatic disease at study entry. Patients were randomized to oral neratinib 240 mg/day or placebo for 1 year. Formalin-fixed, paraffin-embedded primary tumor specimens underwent polymerase chain reaction (PCR) PIK3CA testing for two hotspot mutations in exon 9, one hot-spot mutation in exon 20, and fluorescence in situ hybridization (FISH) analysis for PIK3CA amplification. The primary endpoint (iDFS) was tested with log-rank test and hazard ratios (HRs) estimated using Cox proportional-hazards models. Results Among the intent-to-treat population (n = 2840), tumor specimens were available for PCR testing (991 patients) and PIK3CA FISH (702 patients). Overall, 262 samples were PIK3CA altered: 201 were mutated (77%), 52 (20%) were amplified, and 9 (3%) were mutated and amplified. iDFS was non- significantly worse in placebo- treated patients with altered vs wild-type PIK3CA (HR 1.34 ; 95% CI 0.72–2.50 ; P = 0.357). Neratinib’s effect over placebo was significant in patients with PIK3CA- altered tumors (HR 0.41 ; 95% CI 0.17–0.90, P = 0.028) but not PIK3CA wild-type tumors (HR 0.72 ; 95% CI 0.36–1.41 ; P = 0.34). The interaction test was non-significant (P = 0.309). Conclusions Although there was a greater absolute risk reduction associated with neratinib treatment of patients with PIK3CA- altered tumors in ExteNET, current data do not support PIK3CA alteration as a predictive biomarker of response to neratinib in HER2- positive EBC.

Izvorni jezik
Engleski

POVEZANOST RADA